This Biotech Fund Just Made a $22 Million Bet on Pharvaris Stock — Is It a Buy?

10 months ago 85

Jonathan Ponciano, The Motley Fool

Tue, December 9, 2025 astatine 6:20 AM CST 5 min read

Austin-based Saturn V Capital Management acquired 886,332 shares of Pharvaris successful the 3rd quarter.
Saturn V present holds 886,332 PHVS shares valued astatine $22.1 million.
PHVS is simply a caller addition, accounting for 4.9% of 13F AUM, which places it extracurricular the fund's apical 5 holdings.
These 10 stocks could mint the adjacent question of millionaires ›

On November 14, Austin-based Saturn V Capital Management disclosed a caller presumption successful Pharvaris N.V. (PHVS), acquiring 886,332 shares valued astatine astir $22.1 cardinal during the 3rd quarter.

According to a Securities and Exchange Commission (SEC) filing dated November 14, Saturn V Capital Management initiated a caller presumption successful Pharvaris N.V. (PHVS). The money reported holding 886,332 shares valued astatine $22.1 cardinal astatine quarter-end. This summation expanded its full reportable U.S. equity positions to 17 arsenic of September 30, bringing full money AUM to $456 million.

The PHVS involvement represents astir 4.9% of Saturn V Capital Management LP's 13F AUM.

Top holdings aft this filing:

NASDAQ: ABVX: $68 cardinal (14.9% of AUM)
NASDAQ: AMLX: $62.6 cardinal (13.7% of AUM)
NASDAQ: JAZZ: $39.6 cardinal (8.7% of AUM)
NASDAQ: DYN: $33.8 cardinal (7.4% of AUM)
NASDAQ: COGT: $29.1 cardinal (6.4% of AUM)

As of Monday, shares of Pharvaris N.V. were priced astatine $25.35, up 33% implicit the past twelvemonth and outperforming the S&P 500, which is up 12% successful the aforesaid period.

Metric

Value

Price (as of marketplace adjacent Monday)	$25.35
Market Capitalization	$1.6 billion
Net Income (TTM)	($163.7 million)
1-Year Price Change	33%

Pharvaris focuses connected the improvement of oral therapies for hereditary angioedema (HAE), including PHA121 (Phase II), PHVS416 (on-demand brushed capsule, Phase II), and PHVS719 (prophylactic extended-release tablet, Phase I).
The institution operates arsenic a clinical-stage biopharmaceutical company, generating worth done probe and improvement with the purpose of aboriginal commercialization of proprietary cause candidates for uncommon diseases.
It targets patients suffering from hereditary angioedema, addressing some acute and prophylactic attraction needs successful uncommon illness markets crossed Europe and the United States.

Pharvaris N.V. is simply a clinical-stage biotechnology institution specializing successful the improvement of caller oral therapies for hereditary angioedema (HAE), a uncommon and superior familial disorder. The institution leverages its expertise successful tiny molecule cause plan to beforehand a pipeline of differentiated candidates targeting bradykinin B2-receptor pathways. Pharvaris aims to code important unmet aesculapian needs successful uncommon illness markets, positioning itself for semipermanent maturation arsenic its pb assets advancement done objective development.